grab the latest..
Whitepapers
BEST OF ASCO 2025
Merck mainly focused on KEYTRUDA (pembrolizumab) in endometrial cancer and classic Hodgkin lymphoma indication. The company presented data from KEYVIBE-005 and MK-4280-003 trials
AstraZeneca mainly focused on metastatic breast cancer and gastric cancer. Presented data from the DESTINY-Breast06, DESTINY-Breast09, ARTEMIDE- Gastric01, DESTINY-Gastric05 and DESTINY-Gastric04 trials
TNBC – Molecular subtypes & current SoC
An emerging class of therapies but facing setbacks
Current Development
Discover the process of development, manufacturing, and mitigation of challenges associated with mRNA vaccines
Latest whitepapers
2023 insights into Swissmedic authorization of human medicinal products featuring a new active substance and additional indications
2023 Highlights of European Medicines Agency's human medications recommendations.
What's in store for 2024?
Do these data change practice?
Practice changing or more of the same
Upcoming Papers
To receive an early preview, register with us.
To receive an early preview, register with us.
To receive an early preview, register with us.